Tarsus Stock Analysis

TARS -  USA Stock  

USD 34.81  0.19  0.54%

The latest bullish price patterns experienced by current Tarsus Pharmaceuticals shareholders created some momentum for retail investors as it was traded today as low as 33.35 and as high as 35.23 per share. The company executives have been very successful in rebalancing the company assets at opportune times to take advantage of market volatility in May. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.5. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Tarsus Pharmaceuticals partners.
Additionally, take a look at World Market Map.

Search Stock Analysis 

 
Refresh
The Tarsus Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Tarsus Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Tarsus stock analysis module also helps to analyze the Tarsus Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Tarsus Stock Analysis Notes

The company had not issued any dividends in recent years. Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California. TARS New operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. To find out more about Tarsus Pharmaceuticals contact the company at 949-409-9820 or learn more at http://www.tarsusrx.com.

Tarsus Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Tarsus Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Tarsus Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Tarsus Pharmaceuticals has very high historical volatility over the last 90 days
Tarsus Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (7.3 M).
Tarsus Pharmaceuticals currently holds about 53.13 M in cash with (5.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 20.04.
Latest headline from MacroaxisInsider: Acquisition by Goldberg Andrew D of 10000 shares of Tarsus Pharmaceuticals subject to Rule 16b-3

Tarsus Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Tarsus Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tarsus Pharmaceuticals backward and forwards among themselves. Tarsus Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Tarsus Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Vivo Capital LlcCommon Shares3.2 M104.6 M
Rtw Investments LpCommon Shares2.5 M79.1 M
Frazier Management LlcCommon Shares1.9 M61.8 M
Cormorant Asset Management LpCommon Shares1.7 M55.3 M
Perceptive Advisors LlcCommon Shares1.3 M41.1 M
Timessquare Capital Management LlcCommon Shares451.9 K14.6 M
Blackrock IncCommon Shares339.8 K11 M
Note, although Tarsus Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Tarsus Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 386.06 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Tarsus Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Tarsus Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

Tarsus Pharmaceuticals management efficiency ratios could be used to measure how well tarsus pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 19th of June, Tarsus Pharmaceuticals has the Risk Adjusted Performance of 0.0512, coefficient of variation of 1485.95, and Semi Deviation of 4.72. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tarsus Pharmaceuticals, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Tarsus Pharmaceuticals, which can be compared to its competition. Please validate Tarsus Pharmaceuticals information ratio and downside variance to decide if Tarsus Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 34.81 per share. Given that Tarsus Pharmaceuticals has jensen alpha of 0.2488, we advise you to double-check Tarsus Pharmaceuticals's current market performance to make sure the company can sustain itself at a future point.

Tarsus Pharmaceuticals Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. View also all equity analysis or get more info about mavp overlap studies indicator.

Tarsus Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tarsus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tarsus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tarsus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Tarsus Pharmaceuticals Technical and Predictive Indicators

Tarsus Pharmaceuticals Forecast Models

Tarsus Pharmaceuticals time-series forecasting models is one of many Tarsus Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tarsus Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Tarsus Pharmaceuticals Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Tarsus Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Tarsus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Tarsus Pharmaceuticals. By using and applying Tarsus Stock analysis, traders can create a robust methodology for identifying Tarsus entry and exit points for their positions.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California. TARS New operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Tarsus Pharmaceuticals to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Money Managers Now

   

Money Managers

Screen money managers from public funds and ETFs managed around the world
All  Next Launch Module
Additionally, take a look at World Market Map. Note that the Tarsus Pharmaceuticals information on this page should be used as a complementary analysis to other Tarsus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for Tarsus Pharmaceuticals Stock analysis

When running Tarsus Pharmaceuticals price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
The market value of Tarsus Pharmaceuticals is measured differently than its book value, which is the value of Tarsus that is recorded on the company's balance sheet. Investors also form their own opinion of Tarsus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Tarsus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tarsus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Tarsus Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tarsus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Tarsus Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tarsus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.